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Gram-Scale Synthesis of Luciferins Derived from Coelenterazine and Original Insights in 
Their Bioluminescence Properties 
 
Eloi P. Coutant Sophie Goyard Vincent Hervin Glwadys Gagnot Racha Baatallah Yves Jacob 
Thierry Rose* and Yves L. Janin* 
 
An original gram-scale synthesis of O-acetylated forms of coelenterazine, furimazine or hydroxy-
bearing analogues of these luciferins is described. The comparisons over two hours of their 
bioluminescence, using the nanoKAZ/NanoLuc luciferase, is providing remarkable insights 
useful for the selection of a substrate adapted for a given application. 
 
Introduction 
Bioluminescence is based on the combination of at least oxygen, a small chemical cofactor and 
an enzyme. As depicted in scheme 1, extensive research,1 led to the discovery that many sea-
dwelling bioluminescent species2, 3 are using coelenterazine (CTZ, 1) or varguline (2) and harbor 
a large variety of luciferases or photoproteins (which are calcium-dependent luciferases) to 
produce light with these. Across the years, because of the many uses of bioluminescence-based 
tools in life sciences,4-10 attempts were made to improve the signal intensity, duration and/or the 
emission wavelength. This started with the isolation of a wide range of coelenterazine-using 
luciferases and their combination with analogues of coelenterazine (1). It then moved to the 
analysis of the effect of luciferase mutations on the bioluminescence properties and the best 
results obtained so far were achieved by the association of mutated luciferases and luciferins 
analogues.11-25 It is the combinations of an extensively mutated form of the catalytic subunit of 
Oplophorus gracilirostris luciferase (nanoKAZ/NanoLuc)20, 21 and furimazine (3),20 or 
bisdeoxycoelenterazine (bis-CTZ, 4),21 which appears to be the current state of the art in regard 
with signal intensity and duration. 
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Scheme 1. Structures of coelenterazine (1), varguline (2), furimazine (3), and bisdeoxycoelenterazine (4) and 
retrosynthesis of imidazo[1,2-a]pyrazine-3(7H)-ones. 
 
Concerning the chemistry of these luciferins, they are oxygen-sensitive and readily decompose in 
solution especially in the presence of a base, or upon light exposure.26 As depicted above, many27 
if not all28-30 the reported preparations of imidazo[1,2-a]pyrazin-3(7H)-ones 5 are requiring an 
aminopyrazine (6) prior to the construction of the imidazole ring via a condensation with α-
ketoesters (7) or α-ketoaldehydes (8). Recent improvements have extended this access to original 
luciferins24, 26 but to avoid some of its inherent limitations, we focused on an alternative initially 
explored on a model compound.31 This path not only avoids the use of the non-trivial 
intermediates 7-8, but it also offers, via a key N-arylation of halogenopyrazines (9), the recourse 
to a wide range of the far more available α-amino esters (10).32-34 As depicted in scheme 2, an 
original preparation of chloropyrazines 9a-c was achieved starting with a 1,4-addition reaction 
between β-nitrostyrenes 11a-c and phenylalanine ethyl ester (12). 
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Scheme 2. i: neat. ii: Zn, H3O+, Cl-, dioxane. iii: 130 °C, neat. iv: S8, 1,3-Cl2C6H4, reflux. v: PhPOCl2, 100 °C. vi: 
AcOOH, AcOEt. vii: chlorobenzene, reflux or NaOH, EtOH, reflux. . vii: Cs2CO3, Pd(OAc)2, BINAP, MeCN, 60 °C. 
viii: NaOH, THF, 20 °C. ix: Ac2O, 20 °C. x: H2, Pd/C, AcOEt, AcOH, EtOH. xi: EtOH, DMSO, H3O+, Cl-, 50 °C. 
Until recently,35 there were only very few precedents for this reaction,36-41 probably because of a 
lack of such 1,4-addition in solution. Indeed, in our cases, it is only when removing the solvent 
that the 1,4 adducts 13a-c were formed. The use of zinc and hydrochloric acid in dioxane for their 
reduction provided an access to the diamines 14a-c including a compatibility with the benzyloxy 
groups of 13b-c. Their cyclization to give the (separable) piperazinone diastereoisomers 15a-c 
was then achieved with heat. The previously unreported use of sulfur as an oxidant was initially 
essential for their aromatization into the corresponding hydroxypyrazines 16a-c. Later on, we 
found an alternative via an original dehydration of the N-oxide 17a-b (obtained by the 
peroxyacetic acid treatment of 15a-b) using either heat or more preferably sodium hydroxide. 
Finally, from the hydroxypyrazines 16a-c, hot phenylphosphonic dichloride42 was essential to 
prepare the chloropyrazines 9a-c, and this reagent could also be used to directly transform, for 
instance, N-oxide 17a into the chloropyrazine 9a. This was followed by the key Buchwald-
Hartwig palladium-catalyzed N-arylation of the readily available33, 34 α-amino esters 10A-C by 
chloropyrazines 9a-c. Starting from related precedents,43-48 it quickly turned out that a mild 
temperature was required. The best conditions we found, 60 °C in acetonitrile with cesium 
carbonate for 12 hours using BINAP and palladium(II) acetate, led to the N-arylesters 18 in 69-
90% yields. For the next step, we observed that the inherent instability of the target luciferins 
5aB limited its purification to a precipitation. To avoid this, we prepared the far more stable O-
acetylated derivatives 20 in one pot from the N-arylesters 18 via the acid salts 19, generated in 
situ, and an ensuing treatment with an excess of acetic anhydride. These pro-luciferins turned out 
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to be stable enough to withstand a chromatography but, even better, a simple recrystallization 
provided compounds 20aA-B in up to grams amount. For the synthesis of the phenol-bearing 
luciferins, a catalytic hydrogenation of O-benzyl-bearing compounds 20bA-bC and 20cB-cC 
provided the corresponding O-acetylated luciferins 20dA-dB, 20dD, 20eB and 20eD. Then, as 
seen by LC/MS (supporting information, figure S1), a treatment of these O-acetylated luciferins 
20 with a mixture of hydrochloric acid, ethanol and DMSO at 50 °C provided concentrated 
solutions of the pure luciferins 5 which could be used immediately, upon a dilution in the relevant 
buffer, or stored at low temperature. As depicted in figure 2, and described in the supporting 
information section, the bioluminescence properties of these luciferins were then studied using a 
purified recombinant nanoKAZ/NanoLuc luciferase. In comparison with the very low intensity of 
coelenterazine (1), or for that matter “isocoelenterazine” (5eD), furimazine (3) and 
bisdeoxycoelenterazine (4) were, as previously reported,20, 21 providing vastly improved 
bioluminescence signals lasting at least two hours. Interestingly, the two monohydroxy-bearing 
analogues h-coelenterazine (5dA) and 5dB led to at least twice more intense signals but which 
lasted only minutes (figure 2B). Such initial intensity has actually been reported before for h-
coelenterazine (5dA).21 On the other hand, the isomeric mono hydroxy-bearing compound 5eB 
displayed a far more stable bioluminescence profile pretty much identical with the one observed 
for furimazine (3). With all these luciferins, the light intensity decreased with time: rather quickly 
for the “flash” and much more slowly for the “glow” substrates. For the “flash” substrates, 
luciferins 5dA and 5dB, the decrease fitted with a first order equation.  
  
 
5 
 
 
Figure 2. Bioluminescence signals of the luciferins 5 using recombinant nanoKAZ/NanoLuc. (A) Luciferin 
structures; compounds 1, 3, and 4 are depicted in figure 1. (B) Light intensity in RLU s-1 plotted vs. time over two 
hours, the insert zooms on the first two minutes of the reaction. (C) Bioluminescence profiles of compound 5dB at 
different concentrations along with the repeated addition (arrows) of luciferase. 
Adding further substrate after losing 90% of the initial light emission intensity did not, at best, 
produce any changes and could even causes a decrease of the remaining signal intensity. On the 
other hand, as depicted in figure 2C, adding instead the same amount of enzyme used at the start 
led to a recovery of the signal. For the others substrates, this enzyme death was less pronounced 
but took place anyway (see supporting information). 
Accordingly, the enzyme is irreversibly inactivated by a reaction product in all the cases with a 
constant (kinact) dependent on the substrate used. Of note is that when all the substrate has been 
consumed, the area below these curves is providing a molecules consumed per RLU produced 
ratio (see table 1). Concerning the kinetics of these reactions, they are fitting with a Michaelis-
Menten model, if we assume that the number of detected photons per consumed substrate 
molecule is constant whatever the substrate concentration (see the supporting information for a 
discussion). The KM and Vmax values were computed considering: 1) the luciferins (S) as the 
limiting substrates, O2 as saturating substrate 2) an inhibition of the enzyme E by excess of 
substrate through the binding of a second substrate (ESS) on the Michaelis’ complex (ES) with 
the dissociation constant KI and 3) a stochastic inactivation of the enzyme (E*) with the kinetic 
constant kinact. As seen in table 1 and figure 3, coelenterazine (1) has a very high kcat but a poor 
photon emission efficiency. Interestingly, furimazine (3) and its isomer 5eB are the most efficient 
photon emitter per substrate molecule catalysis with the same kcat but furimazine (3) is somehow 
providing a longer life time of active enzyme (low kinact). All substrates are sensitive to substrate 
concentration beyond the KM, but two luciferins, coelenterazine (1) and 5eD, are more affected 
than others as seen with their low dissociation constants (KI). Of note is that the strong light 
intensity produced by the catalyzed oxidation of 5dB in a very short time (flash) does not mean 
the production of a high level of light intensity cumulated in two hours (ΣI) and the very long 
half-life (t1/2) with low light intensity (glow) provided by compound 5eD neither. Among these 
substrates, furimazine (3) is, so far, providing the best compromise. Also quite unexpected is the 
reason behind the fact that the natural substrate coelenterazine (1) leads to a signal two orders of 
magnitudes less intense than furimazine (3). Indeed, it is not because of a lesser catalytic activity 
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but it is mostly due to a pretty much counter intuitive lesser number of photons detected by 
luciferin consumed. 
Table 1. Kinetic parameters for each substrate. 
 3 4 5dA 5dB 1 5eB 5eD 
Imax         
(106 RLU s-1) 1.69 3.28 2.05 3.11 0.23 1.98 0.10 
t1/2 (min) 74.29 19.34 3.22 0.33 20.96 32.27 148 
ΣI (106 RLU) 84.98 80.85 5.61 11.57 6.29 62.97 6.04 
K’M (10-6 M) 3.40 2.33 3.71 3.45 8.8 4.23 7.02 
k’cat         
(1018 RLU s-1) 1.80 3.50 2.32 3.60 0.44 2.33 0.17 
Molecules/RLU 1775 4581 12067 4463 101169 1804 70020 
KI (10
-6 M) 104.94 115.21 140.55 101.64 22.48 84.02 35.42 
KM (10
-6 M) 2.22 3.02 5.90 3.88 6.80 3.30 2.94 
kcat (mol.s
-1 .molε-1) 106 534 932 535 1500 140 362 
kinact (10
-4 s-1) 1.5 5.2 425 375 3.8 4.5 3.1 
An alternative relative depiction of some of these variables is provided figure 3. 
 
Figure 3 is probably providing a better visual representation of these differences. In comparison 
with the central equidistant triangle representing three characteristics of furimazine (3): 
maximum intensity (Imax), the sum of the signal (ΣI), and half-life of the signal over two hours 
(t1/2), the values for the other substrates can vary widely. Accordingly, the next stage of our 
research will be to find out how specific structural features of the luciferins have an influence on 
these characteristics and more importantly, can such changes lead to even better luciferins. 
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Figure 3. Depiction of the maxima of intensities (Imax), integrated signals (ΣI), and half-time durations (t1/2) for all 
the luciferins, relative to furimazine (3) represented in light grey. 
 
Conclusion 
In conclusion, the results of this work should herald more researches focusing/based on 
bioluminescent reporting systems using imidazo[1,2-a]pyrazine-3(7H)-one luciferins. Indeed, we 
describe here a simple mean to prepare these rather expensive luciferins in such amount that it 
should provide scientists with many more opportunities to design and use such reporting systems. 
The kinetic analyses of light emission presented here are providing rather unexpected insights for 
distinct applications. The glowing property of some substrates is appropriate for high throughput 
in vitro bioassays and long imaging dynamics in vivo or in cellulo, whereas the flashier profile of 
other is appropriate for high sensitivity acquisition systems requiring more light in a short time. 
Moreover, it appears that if the actual catalytic efficiency of nanoKaz/NanoLuc is high, as it is in 
the 102-103 molS/s·molε range, the detection of emitted photons is remarkably modest: only one 
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RLU for more than 1800 decarboxylated molecules at best. Also of note is the fast stochastic 
inactivation seen for some substrate in contrast with other which may reflect the existence of two 
distinct inactivation mechanisms which we are also trying to investigate. In any case, in view of 
all this, we believe that further luciferases mutagenesis and/or design of original luciferin 
analogues could lead to even more improved bioluminescence profiles. 
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Supplementary information 
 
Chemistry 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance 400 spectrometer at 400 MHz 
and 100 MHz, respectively. Shifts (δ) are given in ppm with respect to the TMS signal and cross-
coupling constants (J) are given in Hertz. Column chromatography were performed either on 
Merck silica gel 60 (0.035 - 0.070 mm) or neutral alumina containing 1.5% of added water using 
a solvent pump and an automated collecting system driven by a UV detector set to 254 nm unless 
required otherwise. Sample deposition was carried out by absorption of the mixture to be purified 
on a small amount of the solid phase followed by its deposition of the top of the column. The low 
resolution mass spectra were obtained on an Agilent 1100 series LC/MSD system using an 
atmospheric electrospray ionization system or an Agilent 1200 series LC/MSD system using an 
Agilent Jet-Stream atmospheric electrospray ionization system and the high resolution mass 
spectra (HRMS) were obtained using a Waters Micromass Q-Tof with an electrospray ion source. 
When specified, anhydrous solvents used were purchased. Unless stated otherwise, a purity of at 
least 95% was obtained for all the compounds by means of chromatography, recrystallization or 
distillation and this level of purity was established by TLC, LC/MS and NMR spectroscopy. 
 
Synthesis and separation of (3S,5R) and (3S,5S)-3-benzyl-5-phenylpiperazin-2-ones (15a). 
First step: preparation of nitroethylamine 13a. Commercially available 2-nitrovinylbenzene (11a) 
(3.78 g, 0.025 mol) was added to a freshly extracted free base of L-phenylalanine ethyl ester (4.9 
g, 0.025 mol). The suspension was made homogeneous by the addition of a small amount of 
dichloromethane and the solvent was then removed under vacuum to give a thick oil. Upon 
standing at least 10 minutes, an 1H NMR sample pointed out the occurrence of the 1,4 adducts. A 
complete conversion could never be observed even if the oil was left overnight at room 
temperature. However, a more than 95% conversion was routinely achieved if this oil was left for 
one hour in the present case. Second step: preparation of diamine 14a. The oil mentioned above 
was dispersed in a cold (10 °C) mixture of dioxane (100 mL) and 37% hydrochloric acid (38.7 
mL, 0.33 mol). Zinc dust (7.45 g, 0.11 mol, < 10 µm) was added portion-wise in the course of 10 
minutes while stirring rapidly. The suspension was then allowed to warm to room temperature 
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and stirred for 2 hours. This was diluted in water, made basic with an excess of 22% ammonia 
and extracted with ethyl acetate. The organic layer was washed with a small amount of 22% 
ammonia, water, brine, dried over sodium carbonate and concentrated to dryness to give the 
crude aminoester 14a as an oil. Third step: preparation of compounds 15a. This oil was heated at 
140 °C under argon for 3 hours. The resulting ethanol was removed under vacuum, the solid was 
dispersed in boiling cyclohexane and filtered to remove unreacted L-phenylalanine ester. At this 
stage, the resulting solid can be used directly in the next step or further purified by a 
chromatography over silica gel (dichloromethane / ethanol 96/4 to 95/5) to separate the two 
diasteroisomers of 15a as described below. Note: their structure attribution was easily performed 
by checking for the existence for the first diastereoisomer (or not, for the second diastereoisomer) 
of a nOe effect between their H-3 and H-5. 
 
 
(3S,5R)-3-benzyl-5-phenylpiperazin-2-one (15a, first dia): Obtained as a white solid (2.05 g, 
35%). 1H NMR (CDCl3): 7.42 – 7.29 (m, 9H), 7.23 (m, 1H), 6.27 (s, 1H), 4.06 (dd, 1H, J = 9.7, 
4.7 Hz), 3.84 (dt, 1H, J = 10.1, 3.4 Hz), 3.60 (dd, 1H, J = 13.6, 3.1 Hz), 3.32 (m, 2H), 2.91 (dd, 
1H, J = 13.6, 10.1 Hz), 1.78 (s, 1H). 13C NMR (CDCl3): 171.0, 140.2, 138.4, 129.4, 128.7, 128.7, 
128.2, 126.8, 126.6, 60.9, 57.8, 50.0, 38.4. HRMS (m/z): [M+H]+ calcd for C17H19N2O, 267.1497, 
found: 267.1459. 
 
 
(3S,5S)-3-benzyl-5-phenylpiperazin-2-one (15a, second dia): Obtained as a white solid (1.29 g, 
22%). 1H NMR (CDCl3): 7.46 – 7.18 (m, 10H), 6.44 (s, 1H), 4.27 (dd, 1H, J = 9.6, 4.0 Hz), 3.89 
(dd, 1H, J = 10.7, 3.6 Hz), 3.50 (m, 1H), 3.41 (dt, 1H, J = 11.5, 4.0 Hz), 3.32 (dd, 1H, J = 13.8, 
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3.6 Hz), 3.18 (dd, 1H, J = 13.8, 10.7 Hz), 1.79 (s, 1H). 13C NMR (CDCl3): 171.8, 139.8, 138.0, 
129.3, 128.9, 128.8, 128.2, 126.9, 126.8, 59.4, 51.7, 49.3, 37.8. HRMS (m/z): [M+H]+ calcd for 
C17H19N2O, 267.1497, found: 267.1435. 
 
Synthesis and separation of (3S,5R) and (3S,5S)-3-benzyl-5-(4-(benzyloxy)phenyl)piperazin-
2-one (15b). First step: preparation of nitroethylamine 13b. The 1-(benzyloxy)-4-(2-
nitrovinyl)benzene1 (11b) (3.54 g, 0.013 mol) was added to a freshly extracted free base of L-
phenylalanine ethyl ester (2.68 g, 0.013 mol). The suspension was made homogeneous by the 
addition of a small amount of dichloromethane (30 mL) and the solvent was then removed under 
vacuum to give a thick oil. This was left standing overnight at room temperature to ensure a most 
complete conversion. Second step: preparation of diamine 14b. The oil mentioned above was 
dispersed in a cold (10 °C) mixture of dioxane (50 mL) and 37% hydrochloric acid (20 mL, 0.16 
mol). Zinc dust (3.65 g, 0.055 mol) was added portion-wise in the course of 10 minutes while 
stirring rapidly. The suspension was then allowed to warm to room temperature and stirred for 2 
hours. This was diluted in water, made basic with an excess of 22% ammonia and extracted with 
ethyl acetate. The organic layer was washed with a small amount of 22% ammonia, water and 
brine, dried over sodium carbonate and concentrated to dryness to give the crude aminoester 14b 
as an oil. Third step: preparation of compounds 15b. This oil was heated at 140 °C under argon 
for 3 hours. The resulting ethanol was removed under vacuum and the diasteroisomers of 
compound 15b could be separated as described below. On a larger scale (i.e.: from 12.19 g of 
compound 11b), the crude aminoester 14b was heated at 190 °C in an oil bath under high vacuum 
for how long as it took (20 minutes) to remove the unreacted phenylalanine ethyl ester which 
plagued any purification as well as the aromatization step when using sulfur. Accordingly, this oil 
could be used in the next step (with sulfur) without further purification. Alternatively, also on a 
large scale (22.25 g of compound 11b), the crude compound 15b obtained was then oxidized 
directly into the N-oxide 17b as described below. 
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(3S,5R)-3-benzyl-5-(4-(benzyloxy)phenyl)piperazin-2-one (15b, first dia): This isomer was 
obtained using the first procedure described above as a white powder (0.92 g, 17%) after two 
chromatography over silica gel (dichloromethane - ethanol 95/5 to 92/8) and (cyclohexane - ethyl 
acetate 1/2) and a recrystallization in cyclohexane. 1H NMR (CDCl3): 7.45 – 7.21 (m, 12H), 6.94 
(m, 2H), 6.47 (s (br), 1H), 5.06 (s, 2H), 4.00 (dd, 1H, J = 4.3, 10.1 Hz), 3.83 (dd, 1H, J = 3.0, 
10.1 Hz), 3.59 (dd, 1H, J = 3.0, 13.6 Hz), 3.32 (m, 2H), 2.90 (dd, 1H, J = 10.1, 13.6 Hz), 1.73 (s 
(br), 1H). 13C NMR (CDCl3): 171.1, 158.7, 138.4, 136.9, 132.5, 129.4, 128.7, 128.6, 128.0, 
127.9, 127.4, 126.6, 115.0, 70.1, 60.9, 57.2, 50.0, 38.5. HRMS (m/z): [M+H]+ calcd for 
C25H25N2O3: 373.1916, found: 373.1932. 
 
 
(3S,5S)-3-benzyl-5-(4-(benzyloxy)phenyl)piperazin-2-one (15b, second dia): This isomer was 
obtained using the first procedure described above as a white powder (0.59 g, 11%) after two 
chromatography over silica gel (dichloromethane - ethanol 95/5 to 92/8) and (ethyl acetate - 
ethanol 1/0 to 99/1). 1H NMR (CDCl3): 7.45 – 7.23 (m, 12H), 6.96 (m, 2H), 6.67 (s (br), 1H), 
5.07 (s, 2H), 4.21 (dd, 1H, J = 4.0, 9.6 Hz), 3.85 (dd, 1H, J = 3.5, 10.7 Hz), 3.40 (m, 2H), 3.31 
(dd, 1H, J = 3.5, 13.8 Hz), 3.18 (dd, 1H, J = 10.7, 13.7 Hz), 1.76 (s (br), 1H). 13C NMR (CDCl3): 
171.9, 158.7, 138.0, 136.9, 132.2, 129.3, 128.9, 128.6, 128.1, 128.0, 127.4, 126.8, 115.0, 70.1, 
59.4, 51.1, 49.3, 37.6. HRMS (m/z): [M+H]+ calcd for C25H25N2O3: 373.1916, found: 373.1907. 
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Synthesis and separation of (3S,5R) and (3S,5S)-3-benzyl-5-(3-(benzyloxy)phenyl)piperazin-
2-one (15c). First step: preparation of nitroethylamine 13c. The 1-(benzyloxy)-3-(2-
nitrovinyl)benzene (11c)2 (10.77 g, 0.042 mol), L-phenylalanine ethyl ester hydrochloride (9.69 
g, 0.042 mol) and triethylamine (4.48 g, 0.044 mol) were stirred in dichloromethane (50 mL) for 
10 minutes and the solvent was removed under vacuum to give a thick oil. This was left standing 
overnight at room temperature to ensure a most complete conversion. Second step: preparation of 
diamine 14c. The oil mentioned above was dispersed in a cold (10 °C) mixture of dioxane (100 
mL) and 37% hydrochloric acid (41 mL, 0.506 mol). Zinc dust (10.9 g, 0.168 mol) was added 
portion-wise in the course of 10 minutes while stirring rapidly. The suspension was then allowed 
to warm to room temperature and stirred for 2 hours. This was diluted in water, made basic with 
an excess of 22% ammonia and extracted with ethyl acetate. The organic layer was washed with a 
small amount of 22% ammonia, water and brine, dried over sodium carbonate and concentrated 
to dryness to give the crude aminoester 14c as an oil. Third step: preparation of compounds 15c. 
This oil was heated at 140 °C under argon for 3 hours. The resulting ethanol was removed under 
vacuum and the residue extracted with boiling cyclohexane, the extract left to crystallize to yield 
(in two crops) compound 15c as a mixture of the two diasteroisomers (4.92 g, 31%). The 
insoluble material and the filtrates were concentrated to dryness and additional amount of the two 
(separated) diasteroisomers (1.64 g and 1.77 g, 21% in total) were obtained from this residue as 
described below. 
 
 
(3S,5R)-3-benzyl-5-(3-(benzyloxy)phenyl)piperazin-2-one (15c, first dia): This isomer was 
obtained from the recrystallization residue described above as a white powder (1.64 g), still 
containing 3% of an unidentified material, after two chromatography over silica gel 
(dichloromethane - ethanol 97/3 to 96/4), (cyclohexane – ethyl acetate 2/3) and a recrystallization 
in cyclohexane. 1H NMR (DMSO-d6): 7.75 (d (br), 1H, J = 4.0 Hz), 7.46-7.15 (m, 11H), 7.05 (m, 
1H), 6.95 (m, 1H), 6.90 (m, 1H), 5.08 (s, 2H), 3.97 (m, 1H), 3.67 (m, 1H), 3.27 (dd, 1H, J = 13.8, 
3.63 Hz), 3.20 (dt, 1H, J = 11.3, 4Hz), 3.03 (t, 1H, J = 10.9 Hz), 2.82 (dd, 1H, J = 13.9, 8.6 Hz), 
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2.31 (m, 1H). 13C NMR (DMSO-d6): 170.2, 158.8, 143.4, 139.7, 137.5, 129.9, 129.8, 128.9, 
128.5, 128.3, 128.1, 126.4, 119.6, 114.1, 113.8, 69.6, 60.3, 56.7, 49.2, 38.1. HRMS (m/z): 
[M+H]+ calcd for C24H25N2O2: 373.1916, found: 373.1919. 
 
 
(3S,5S)-3-benzyl-5-(3-(benzyloxy)phenyl)piperazin-2-one (15c, second dia): This isomer was 
obtained from the recrystallization residue described above as a white powder (1.77 g) after a 
chromatography over silica gel (dichloromethane - ethanol 97/3 to 96/4) and a dispersion in 
boiling cyclohexane. 1H NMR (DMSO-d6): 7.81 (d (br), 1H, J = 3.0 Hz), 7.45-7.31 (m, 5H), 7.28 
– 7.16 (m, 6H), 7.04 (m, 1H), 6.91 (m, 2H), 5.05 (s, 2H), 4.06 (m, 1H), 3.52 (m, 1H), 3.29 (m, 
1H), 3.21 (m, 1H), 3.03 (m, 2H), 2.45 (s (br), 1H). 13C NMR (DMSO-d6): 171.2, 158.9, 143.3, 
139.9, 137.6, 129.8, 129.7, 128.9, 128.6, 128.3, 128.1, 126.5, 119.6, 114.0, 113.8, 69.6, 58.7, 
51.2, 48.3, 37.8. HRMS (m/z): [M+H]+ calcd for C24H25N2O2: 373.1916, found: 373. 1926. 
 
General procedure for the synthesis of compounds 16a-c using sulfur. The considered 
piperazin-2-one (0.011 mol) and sulfur (0.72 g, 0.0225 mol) were heated to reflux in 1,3-
dichlorobenzene (40 mL) for 10 hours. This was concentrated to dryness and the residue purified 
as described below. On a larger scale, the residue was routinely taken up directly in the next step 
to obtain the chloropyrazines 9 as described. 
 
 
3-Benzyl-5-phenylpyrazin-2-ol (16a): This compound was obtained as a white powder (2.28 g, 
73%) after a chromatography over silica gel (dichloromethane – ethanol 98/2 to 97/3). 1H NMR 
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(DMSO-d6) 12.41 (s, 1H), 7.85 (m, 3H), 7.40 (m, 4H), 7.30 (m, 3H), 7.20 (m, 1H), 4.07 (s, 2H). 
13C NMR (DMSO-d6): 157.4, 155.4, 138.4, 136.4, 131.4, 129.6, 129.1, 128.7, 127.7, 126.7, 
124.9, 122.9, 39.3. HRMS (m/z): [M+H]+ calcd for C17H15N2O: 263.1184, found, 263.1118. 
 
 
3-Benzyl-5-(4-(benzyloxy)phenyl)pyrazin-2-ol (16b): This compound was obtained as a powder 
(0.8 g, 62%) after a chromatography over silica gel (dichloromethane - ethanol 98/2). 1H NMR 
(DMSO-d6) 12.31 (s, 1H), 7.78 (m, 2H), 7.40 (m, 4H), 7.37 (m, 9H), 7.19 (m, 1H), 7.03 (m, 2H), 
5.13 (s, 2H), 4.06 (s, 2H). 13C NMR (DMSO-d6): 157.8, 156.5, 154.8, 137.9, 137.0, 131.2, 129.0, 
128.8, 128.4, 128.2, 127.7, 127.6, 126.1, 125.8, 121.5, 114.9, 69.2, 38.8. HRMS (m/z): [M+H]+ 
calcd for C24H22N2O2: 369.1603, found, 369.1603. 
 
 
3-Benzyl-5-(3-(benzyloxy)phenyl)pyrazin-2-ol (16c): This compound was obtained as beige solid 
(1.41 g, 54%) as described above but using boiling decaline (30 mL) instead of 1,3-
dichlorobenzene after a chromatography over silica gel (cyclohexane – ethyl acetate 2/1 to 1/1). 
1H NMR (DMSO-d6) 12.42 (s (br), 1H), 7.92 (s, 1H), 7.50-7.27 (m, 12H), 7.20 (m, 1H), 6.94 (m, 
1H), 5.13 (s, 2H), 4.07 (s, 2H). 13C NMR (DMSO-d6): 159.2, 157.3, 155.5, 138.3, 137.9, 137.6, 
131.0, 130.2, 129.7, 128.9, 128.7, 128.3, 128.1, 126.6, 123.1, 117.5, 114.2, 111.3, 69.7, 39.3. 
HRMS (m/z): [M+H]+ calcd for C24H22N2O2: 369.1603, found, 369. 1609. 
 
General procedure for the synthesis of the N-oxide 17a-b: 
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6-Benzyl-5-oxo-2-phenyl-2,3,4,5-tetrahydropyrazine 1-oxide (17a): To 3-benzyl-5-
phenylpiperazin-2-one (0.44 g, 1.65 mmol) dissolved in acetic acid (5 mL) was added a 36% 
solution of peracetic acid in acetic acid (0.77 g, 3.63 mmol). This was stirred overnight, diluted in 
ethyl acetate, washed with water, brine, dried over molecular sieve and concentrated to dryness. 
The residue was purified by a chromatography over silica gel (cyclohexane – ethyl acetate 1/1 to 
1/2) to yield the N-oxide (0.26 g, 56%) as a white powder. Nota, COSY correlations firmly 
established the structures of this compound. 1H NMR (CDCl3): 7.43 (m, 2H), 7.35-7.20 (m, 6H), 
7.15 (m, 2H), 6.84 (s (br), 1H), 5.12 (t, 1H, J = 4.4 Hz), 4.13 (s, 2H), 4.00 (dd, 1H, J = 4.4, 13.3 
Hz), 3.63 (dt, 1H, J = 4.4, 13.3 Hz). 13C NMR (CDCl3): 161.2, 141.7, 136.0, 134.2, 129.6, 129.1, 
129.0, 128.4, 126.7, 126.6, 71.8, 43.1, 30.2. HRMS (m/z): [M+H]+ calcd for C17H17N2O2: 
281.1190, found, 281.1234. 
 
 
6-Benzyl-2-(4-(benzyloxy)phenyl)-5-oxo-2,3,4,5-tetrahydropyrazine 1-oxide (17b): The crude 
piperazin-2-one 16b obtained from compound 11b (0.0871 mol) as described above was 
dissolved in ethyl acetate (600 mL), 35% peracetic acid in acetic acid (33.8 mL, 0.174 mol) was 
added and this was stirred for 24 hours. The precipitate was filtered, washed with ethyl acetate 
and dried to yield compound 17b (5.40 g, 16% from nitrostyrene 11b). The filtrate was washed 
with water, brine, dried over magnesium sulfate, concentrated to dryness and the residue purified 
by chromatography over silica gel (cyclohexane – ethyl acetate 1/1 to 1/2) to yield more of 
compound 17b (7.31 g, 21% from nitrostyrene 11b). 1H NMR (DMSO-d6) 8.31 (d (br), 1H, J = 
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3.8 Hz), 7.44-7.17 (m, 10H), 7.14 (m, 2H), 6.97 (m, 2H), 5.17 (m, 1H), 5.10 (s, 2H), 3.94 (m, 
3H), 3.53 (dt, 1H, J = 4.5, 14.0 Hz). 13C NMR (DMSO-d6): 160.7, 158.8, 140.7, 137.4, 137.2, 
129.3, 128.9, 128.6, 128.5, 128.3, 128.1, 128.0, 126.7, 71.0, 69.7, 42.6, 30.2 (one signal missing). 
HRMS (m/z): [M+H]+ calcd for C24H23N2O3: 387.1709, found, 387.1714. 
 
Procedure for the synthesis of compounds 16a via a thermal dehydration of the N-oxide 
17a. In a microwave-adapted vial, a crude batch of 6-benzyl-5-oxo-2-phenyl-2,3,4,5-
tetrahydropyrazine 1-oxide (0.41 g, 1.46 mmol) obtained as described above was dissolved in 
chlorobenzene (5 mL). This was sealed and heated in a microwave oven at 190 °C for two hours. 
The solvent was removed in vacuum and the residue purified by a chromatography over silica gel 
(cyclohexane – ethyl acetate 3/2) to give 3-benzyl-5-phenylpyrazin-2-ol 16a (0.20 g, 52% from 
3-benzyl-5-phenylpiperazin-2-one 15a) with analytical data identical with the one described 
above. 
 
Procedure for the synthesis of compounds 16a-b via a sodium hydroxide - based 
rearrangement of the N-oxides 17a-b, representative procedure. The N-oxide 17b (7.31 g, 
0.0189 mol) and sodium hydroxide (2.26 g, 0.0567 mol) were heated to reflux in ethanol (90 mL) 
for one hour. This was diluted in water, made acid with hydrochloric acid, the precipitate was 
filtered, washed with water and dried under vacuum at 60 °C to yield compound 16b (6.66 g, 
95%) as described above. Note: from a sample of compound 17a (0.11 g, 0.39 mmol), the same 
protocol gave compound 16a (0.09 g, 87%) as described above. 
 
General procedure for the synthesis of compounds 9a-c: under a calcium-protected 
atmosphere, the considered 2-hydroxypyrazine (0.02 mol) was dispersed in phenylphosphonic 
dichloride (10 mL) and the suspension was heated at 100 °C for the indicated time. The resulting 
solution was diluted in ethyl acetate and poured onto an excess of crushed ice and stirred for 15 
min. This was made basic with 22% ammonia and extracted with ethyl acetate. The organic layer 
was washed with water, brine, dried over magnesium sulfate and concentrated to dryness. The 
resulting residues were purified as described below. 
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3-benzyl-2-chloro-5-phenylpyrazine (9a): Obtained as a yellowish solid (1.60 g, 82%) after a 
chromatography over silica gel (cyclohexane-dichloromethane 3:2). Alernatively, this compound 
was obtained in 36% yield under the same reaction conditions but using the N-oxide 17a. Note: 
From the crude mixture of compound 15a obtained by a simple dispertion in boiling cyclohexane 
as described above and undertaking the next two synthetic steps (sulfur-based aromatization and 
chlorodehydroxylation) whithout any chromatography, batches of the pure compound 9a (20.04 
g, 62% from 11a) were routinely obtained after a single chromatography over silica gel 
(dichloromethane-ethanol 97/3 to 96.5/3.5). 1H NMR (CDCl3): 8.68 (s, 1H), 8.04 (m, 2H), 7.55 
(m, 3H), 7.42 (m, 2H), 7.35 (m, 2H), 7.28 (m, 1H), 4.41 (s, 2H). 13C NMR (CDCl3): 153.6, 150.4, 
146.9, 138.6, 137.1, 135.4, 130.0, 129.2, 129.1, 128.5, 126.9, 126.8, 41.2. HRMS (m/z): [M+H]+ 
calcd for C17H14ClN2, 281.0846, found, 281.0730. 
 
 
3-Benzyl-5-(4-(benzyloxy)phenyl)-2-chloropyrazine (9b): Obtained as a yellow solid (5.66 g, 
62%) after heating for 18 hours and a chromatography over silica gel (cyclohexane-
dichloromethane 1/1). 1H NMR (CDCl3): 8.61 (s, 1H), 8.0 (m, 2H), 7.47-7.20 (m, 10H), 7.11 (m, 
2H), 5.17 (s, 2H), 4.38 (s, 2H). 13C NMR (CDCl3): 161.5, 153.3, 150.1, 145.9, 138.0, 137.2, 
136.6, 129.2, 128.7, 128.5, 128.3, 128.1, 127.9, 127.4, 126.7, 115.4, 70.1, 41.2 (one signal 
missing). HRMS (m/z): [M+H]+ calcd for C24H20ClN2O, 387.1264, found, 387.1266. 
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3-Benzyl-5-(3-(benzyloxy)phenyl)-2-chloropyrazine (9c): Obtained as a slowly solidifying oil 
(0.77 g, 61%) after heating for 18 hours and a chromatography over silica gel (cyclohexane-ethyl 
acetate 97/3). 1H NMR (CDCl3): 8.65 (s, 1H), 7.69 (m, 1H), 7.60 (m, 1H), 7.50 (m, 2H), 7.45-
7.32 (m, 8H), 7.27 (m, 1H), 7.11 (m, 1H), 5.17 (s, 2H), 4.40 (s, 2H). 13C NMR (CDCl3): 159.4, 
153.6, 150.0, 147.0, 138.6, 137.1, 136.8, 136.7, 130.1, 129.3, 128.7, 128.5, 128.1, 127.6, 126.8, 
119.4, 116.7, 113.4, 70.2, 41.2. HRMS (m/z): [M+H]+ calcd for C24H20ClN2O, 387.1264, found, 
387.1262. 
 
General procedure for the N-arylation of chloropyrazines 9a-c by α-aminoesters. In a 20 mL 
sealable vial, the considered 2-halogenopyrazine (1 mmol), the considered α-aminoesters3, 4 (1.1 
mmol, either as a free base or as a hydrochloride salt), cesium carbonate (1.04 g, 3.2 mmol), 
palladium acetate (0.011 g, 0.05 mmol,) and 1,1′-binaphthalene-2,2′-diyl)bis(diphenylphosphine) 
(BINAP) (0.047 g, 0.075 mmol) were weighted. The air was replaced by argon and dry 
acetonitrile (4 mL) was injected. This was heated under an inert atmosphere (a balloon inflated 
with argon) at 60 °C for 12 hours using an oil bath along with fast stirring to break up any clumps 
of cesium hydrogen carbonate forming. The resulting dark red or black suspension was dispersed 
in dichloromethane, this was filtered, rinsed with dichloromethane and the filtrate was 
concentrated to dryness prior further purifications as described below. Note: on larger scale, a 
flask fitted with a rubber septum and a balloon inflated with argon worked as fine. 
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Ethyl (3-benzyl-5-phenylpyrazin-2-yl)phenylalaninate (18aA): Obtained as an oil (1.07 g, 69%) 
after a chromatography over silica gel (dichloromethane). 1H NMR (CDCl3): 8.43 (s, 1H), 7.96 
(m, 2H), 7.49 (m, 1H), 7.37 (m, 1H), 7.33 – 7.20 (m, 8H), 7.90 (m, 2H), 4.97 (m, 2H), 4.14 (s, 
2H), 4.13 (q, 2H, J = 7.1 Hz), 3.18 (dd, 1H, J = 13.8, 5.4 Hz), 3.09 (dd, 1H, J = 13.8, 5.9 Hz), 
1.20 (t, 3H, J = 7.1 Hz). 13C NMR (CDCl3): 172.4, 150.4, 141.2, 141.1, 137.5, 136.9, 136.5, 
136.3, 129.3, 128.8, 128.7, 128.6, 128.4, 127.8, 126.9, 126.9, 125.7, 61.2, 54.9, 40.9, 37.8, 14.1. 
HRMS (m/z): [M+H]+ calcd for C28H28N3O2, 438.2182, found, 438.2185. 
 
 
Ethyl 2-((3-benzyl-5-phenylpyrazin-2-yl)amino)-3-(furan-2-yl)propanoate (18aB): obtained as an 
oil (6.31 g, 89%) after a chromatography over silica gel (cyclohexane-ethyl acetate 95:5). 1H 
NMR (CDCl3): 8.42 (s, 1H), 7.95 (m, 2H), 7.46 (m, 2H), 7.39 – 7.28 (m, 5H), 7.22 (m, 2H), 6.22 
(dd, 1H, J = 3.2, 1.9 Hz), 5.85 (dd, 1H, J = 3.2, 0.7 Hz), 5.13 (d, 1H, J = 7.5 Hz), 4.95 (dt, 1H, J 
= 7.5, 5.3 Hz), 4.16 (m, 4H), 3.21 (m, 2H), 1.22 (t, 3H, J = 7.1 Hz). 13C NMR (CDCl3): 172.0, 
150.6, 150.3, 141.9, 141.2, 141.1, 137.5, 136.8, 136.6, 128.8, 128.7, 128.7, 127.8, 126.8, 125.7, 
110.3, 107.7, 61.3, 53.2, 40.9, 30.4, 14.1. HRMS (m/z): [M+H]+ calcd for C26H26N3O3, 428.1974, 
found: 428.1965. 
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Ethyl (3-benzyl-5-(4-(benzyloxy)phenyl)pyrazin-2-yl)phenylalaninate (18bA): Obtained, as a 
white solid (4.47 g, 87%) after a chromatography over silica gel (cyclohexane – ethyl acetate 
95/5 to 94/6). 1H NMR (CDCl3): 8.36 (s, 1H), 7.89 (m, 2H), 7.49 (m, 2H), 7.42 (m, 2H), 7.35 (m, 
1H), 7.32-7.20 (m, 8H), 7.08 (m, 2H), 7.00 (m, 2H), 5.15 (s, 2H), 4.97 (m, 1H), 4.86 (d(br), 1H, J 
= 8.1 Hz), 4.14 (m, 4H), 3.17 (dd, 1H, J = 5.5, 13.8 Hz), 3.08 (dd, 1H, J = 6.0, 13.8 Hz), 1.19 (t, 
3H, J = 7.2 Hz). 13C NMR (CDCl3): 172.4, 158.8, 149.9, 141.1, 141.0, 137.0, 136.6, 136.3, 
136.1, 130.5, 129.3, 128.8, 128.6, 128.5, 128.4, 128.0, 127.4, 126.9, 126.8, 126.7, 115.2, 70.1, 
61.2, 54.9, 40.8, 37.9, 14.1. HRMS (m/z): [M+H]+ calcd for C35H34N3O3, 544.2600, found, 
544.2609. 
 
 
Ethyl 2-((3-benzyl-5-(4-(benzyloxy)phenyl)pyrazin-2-yl)amino)-3-(furan-2-yl)propanoate 
(18bB): Obtained as an oil (0.83 g, 79%) after a chromatography over silica gel (cyclohexane – 
ethyl acetate 94/6 to 93/7). 1H NMR (CDCl3): 8.35 (s, 1H), 7.89 (m, 2H), 7.48 (m, 2H), 7.42 (m, 
2H), 7.36 (m, 1H), 7.32-7.20 (m, 6H), 7.08 (m, 2H), 6.22 (dd, 1H, J = 2.0, 3.0 Hz), 5.85 (dd, 1H, 
J = 0.7, 3.0 Hz), 5.15 (s, 2H), 5.07 (d(br), 1H, J = 7.6 Hz), 4.94 (m, 1H), 4.16 (m, 4H), 3.20 (d, 
2H, J = 5.3 Hz), 1.21 (t, 3H, J = 7.2 Hz). 13C NMR (CDCl3): 172.0, 158.8, 150.6, 149.9, 141.9, 
141.1, 141.0, 137.0, 136.6, 136.1, 130.5, 128.8, 128.7, 128.6, 127.9, 127.4, 126.9, 126.8, 115.2, 
110.3, 107.7, 70.1, 61.2, 53.2, 40.8, 30.5, 14.1. HRMS (m/z): [M+H]+ calcd for C33H32N3O4, 
534.2393, found, 534.2410. 
 
 
24 
 
Ethyl 2-((3-benzyl-5-(4-(benzyloxy)phenyl)pyrazin-2-yl)amino)-3-(4-
(benzyloxy)phenyl)propanoate (18bC): Obtained as an oil (1.17 g, 70%) after a chromatography 
over silica gel (cyclohexane – ethyl acetate 91/9 to 9/1). 1H NMR (CDCl3): 8.34 (s, 1H), 7.88 (m, 
2H), 7.45 (m, 4H), 7.40 (m, 4H), 7.34 (m, 2H), 7.25 (m, 3H), 7.20 (m, 2H), 7.06 (m, 2H), 6.91 – 
6.77 (m, 4H), 5.13 (s, 2H), 5.05 (s, 2H), 4.90 (m, 1H), 4.83 (m, 1H), 4.11 (m, 4H), 3.10 (dd, 1H, 
J = 13.9, 5.4 Hz), 3.01 (dd, 1H, J = 13.9, 5.9 Hz), 1.19 (t, 3H, J = 7.1 Hz). 13C NMR (CDCl3): 
172.7, 158.9, 157.9, 150.1, 141.2, 141.1, 137.2, 136.8, 136.3, 130.7, 130.4, 128.9, 128.8, 128.7 (3 
signals), 128.1, 127.6, 127.0, 115.4, 115.0, 70.2, 61.2, 55.1, 41.0, 37.1, 14.3. HRMS (m/z): 
[M+H]+ calcd for C42H40N3O4, 650.3019, found, 650.3049. 
 
 
Ethyl 2-(3-benzyl-5-(3-(benzyloxy)phenyl)pyrazin-2-ylamino)-3-(furan-2-yl)propanoate (18cB): 
Obtained as an oil (0.63 g, 90%, still containing traces of EtOAc) after a chromatography over 
silica gel (cyclohexane – ethyl acetate 97/3 to 96/4). 1H NMR (CDCl3): 8.39 (s, 1H), 7.63 (m, 
1H), 7.50 (m, 3H), 7.43-7.24 (m, 11H), 6.99 (m, 1H), 6.23 (dd, 1H, J = 3.1, 2.0 Hz), 5.85 (d, 1H, 
J = 3.2 Hz), 5.16 (s, 2H), 5.15 (d, 1H, J = 6.1 Hz), 4.96 (m, 1H), 4.17 (s, 2H), 4.16 (q, 2H, J = 
7.1 Hz), 3.21 (m, 2H), 1.22 (t, 3H, J = 7.1 Hz). 13C NMR (CDCl3): 171.9, 159.4, 150.6, 150.3, 
141.9, 141.2, 140.7, 138.9, 137.1, 136.7, 136.5, 129.8, 128.8, 128.7, 128.6, 127.9, 127.6, 126.9, 
118.2, 114.5, 112.2, 110.3, 107.7, 70.1, 61.3, 53.2, 40.8, 30.4, 14.1 (one signal missing). HRMS 
(m/z): [M+H]+ calcd for C33H32N3O4, 534.2393, found, 534.2402. 
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Ethyl 2-(3-benzyl-5-(3-(benzyloxy)phenyl)pyrazin-2-ylamino)-3-(4-
(benzyloxy)phenyl)propanoate (18cC): Obtained as an oil (0.50 g, 78%) after a chromatography 
over silica gel (cyclohexane – ethyl acetate 97/3 to 96/4). 1H NMR (CDCl3): 8.40 (s, 2H), 7.65 
(m, 1H), 7.65-7.20 (m, 17H), 6.99 (m, 1H), 6.88 (m, 2H), 6.83 (m, 2H), 5.17 (s, 2H), 5.07 (s, 
2H), 4.94 (m, 2H), 4.14 (m, 4H), 3.13 (m, 1H), 3.013 (m, 1H), 1.21 (t, 3H, J = 7.1 Hz). 13C NMR 
(CDCl3): 172.4, 159.4, 157.8, 150.2, 141.3, 140.6, 138.8, 137.2, 137.1, 136.4, 136.3, 130.3, 
129.8, 128.8, 128.7, 128.6, 128.4, 128.0, 127.9, 127.6, 127.4, 126.9, 118.2, 114.9, 114.5, 112.2, 
70.1, 70.0, 61.2, 55.0, 40.8, 36.9, 14.1 (one signal missing). HRMS (m/z): [M+H]+ calcd for 
C42H40N3O4, 650. 3019, found, 650. 3016. 
 
Procedure for the synthesis of O-acetylated compounds 20aA-B, 20b-C, 20cB-C. In a 
sealable vessel, the considered N-pyrazyl aminoester 18 (1.0 mmol) and sodium hydroxide (0.16 
g, 4 mmol) were weighted. The air was replaced with argon and anhydrous THF (5 mL) was 
injected. This was stirred at 20 °C under an inert atmosphere (a balloon inflated with argon) 
overnight and acetic anhydride (1.4 mL, 15.0 mmol) was then injected. After stirring an 
additional two hours under an inert atmosphere at room temperature, this was diluted in ethyl 
acetate, washed with water, brine and concentrated to dryness. The traces of acetic acid and 
acetic anhydride were removed by co-evaporation with toluene and then cyclohexane and the 
residue further purified as described below. 
 
 
2,8-Dibenzyl-6-phenylimidazo[1,2-a]pyrazin-3-yl acetate (20aA): Obtained as a yellowish solid 
(0.17 g, 50%) after a recrystallization in cyclohexane. 1H NMR (CDCl3): 7.92 (m, 2H), 7.80 (s, 
1H), 7.64 (m, 2H), 7.47 (m, 2H), 7.40 (m, 1H), 7.33 (m, 5H), 7.25 (m, 2H), 4.65 (s, 2H), 4.23 (s, 
2H), 2.18 (s, 3H). 13C NMR (CDCl3): 167.1, 152.9, 139.1, 137.9, 137.8, 136.8, 135.1, 133.5, 
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129.8, 129.1, 128.9, 128.8, 128.6, 128.5, 128.3, 126.5 (two signals), 126.4, 108.8, 39.4, 34.2, 
19.9. HRMS (m/z): [M+H]+ calcd for C28H24N3O2, 434.1869, found, 434.1825. 
 
 
8-benzyl-2-(furan-2-ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3-yl acetate (20aB): Obtained as 
an off-white solid (4.02 g, 72%) after a recrystallization in cyclohexane. 1H NMR (CDCl3): 7.92 
(m, 2H), 7.83 (s, 1H), 7.63 (m, 2H), 7.47 (m, 2H), 7.42-7.30 (m, 4H), 7.23 (m, 1H), 6.35 (m, 1H), 
6.16 (m, 1H), 4.64 (s, 2H), 4.24 (s, 2H), 2.36 (s, 3H). 13C NMR (CDCl3): 167.0, 153.0, 151.5, 
141.5, 139.2, 137.8, 136.7, 133.5, 132.5, 129.7, 128.9, 128.8, 128.6, 128.3, 126.5, 126.4, 110.5, 
108.9, 106.8, 39.3, 27.2, 20.1. HRMS (m/z): [M+H]+ calcd for C26H22N3O3, 424.1661, found, 
424.1607. 
 
 
2,8-Dibenzyl-6-(4-(benzyloxy)phenyl)imidazo[1,2-a]pyrazin-3-yl acetate (20bA): Obtained as an 
off-white solid (0.44 g) pure enough (traces of THF and acetic acid) to be used directly in the 
next step. 1H NMR (CDCl3): 7.83 (m, 2H), 7.72 (s, 1H), 7.63 (m, 2H), 7.47 (m, 2H), 7.48-7.21 
(m, 13H), 5.15 (s, 2H), 4.64 (s, 2H), 4.22 (s, 2H), 2.18 (s, 3H). 13C NMR (CDCl3): 167.1, 159.3, 
152.7, 139.0, 138.1, 137.9, 136.9, 135.0, 133.4, 129.7, 129.6, 129.1, 128.8, 128.6, 128.5, 128.3, 
128.0, 127.7, 127.4, 126.5, 126.4, 115.2, 107.9, 70.1, 39.4, 34.2, 19.8. HRMS (m/z): [M+H]+ 
calcd for C35H30N3O3, 540.2287, found, 540.2275. 
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8-Benzyl-6-(4-(benzyloxy)phenyl)-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3-yl acetate 
(20bB): Obtained as an off-white solid (1.13 g) pure enough (traces of acetic acid) to be used 
directly in the next step. 1H NMR (CDCl3): 7.85 (m, 2H), 7.75 (s, 1H), 7.61 (m, 2H), 7.47 (m, 
2H), 7.44-7.21 (m, 7H), 7.07 (m, 2H), 6.37 (m, 1H), 6.16 (m, 1H), 5.15 (s, 2H), 4.62 (s, 2H), 4.24 
(s, 2H), 2.35 (s, 3H). 13C NMR (CDCl3): 167.1, 159.3, 152.8, 151.5, 141.6, 139.1, 137.8, 136.8, 
133.4, 132.3, 129.7, 129.6, 128.8, 128.6, 128.3, 128.0, 127.7, 127.4, 126.4, 115.2, 110.5, 107.9, 
106.8, 70.1, 39.3, 27.2, 20.1. HRMS (m/z): [M+H]+ calcd for C33H28N3O4, 530.2080, found, 
530.2070. 
 
 
8-Benzyl-2-(4-(benzyloxy)benzyl)-6-(4-(benzyloxy)phenyl)imidazo[1,2-a]pyrazin-3-yl acetate 
(20bC): Obtained as an off-white solid (0.51 g) which was used directly in the next step. 1H 
NMR (CDCl3): 7.84 (m, 2H), 7.71 (s, 1H), 7.61 (m, 2H), 7.48 – 7.29 (m, 12H), 7.25 – 7.20 (m, 
3H), 7.06 (m, 2H), 6.94 (m, 2H), 5.14 (s, 2H), 5.09 (s, 2H), 4.62 (s, 2H), 2.17 (s, 3H). 13C NMR 
(CDCl3): 167.1, 159.3, 157.9, 152.7, 138.9, 137.9, 137.1, 136.9, 135.4, 133.5, 130.4, 130.0, 
129.7, 128.7, 128.6, 128.5, 128.2, 128.0, 127.9, 127.7, 127.5, 127.4, 126.4, 115.2, 114.9, 107.8, 
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70.1, 70.0, 39.4, 33.4, 26.9, 19.9. HRMS (m/z): [M+H]+ calcd for C42H36N3O4, 646.2706, found, 
646.2728. 
 
 
8-Benzyl-6-(3-(benzyloxy)phenyl)-2-(furan-2-ylmethyl)imidazo[1,2-a]pyrazin-3-yl acetate 
(20cB): Obtained as an oil (0.55 g) still containing a small amount of cyclohexane which was 
used in the next step without further purification. 1H NMR (CDCl3): 7.83 (s, 1H), 7.61 (m, 3H), 
7.49 (m, 3H), 7.45-7.21 (m, 8H), 7.02 (m, 1H), 6.36 (dd, 1H, J = 3.1, 1.9 Hz), 6.17 (dd, 1H, J = 
3.2, 0.8 Hz), 5.14 (s, 2H), 4.65 (s, 2H), 4.25 (s, 2H), 2.36 (s, 3H). 13C NMR (CDCl3): 167.0, 
159.3, 152.9, 151.4, 141.7, 138.9, 138.1, 137.7, 136.9, 133.4, 132.4, 129.8 (two signals), 128.9, 
128.6, 128.3, 128.0, 127.6, 126.5, 118.8, 115.1, 113.3, 110.5, 109.0, 106.9, 70.2, 39.3, 27.1, 20.1. 
HRMS (m/z): [M+H]+ calcd for C33H28N3O4, 530.2080, found, 530.2084. 
 
 
8-Benzyl-2-(4-(benzyloxy)benzyl)-6-(3-(benzyloxy)phenyl)imidazo[1,2-a]pyrazin-3-yl acetate 
(20cC): Obtained as a white solid (0.5 g, 77%) after a recrystallization in cyclohexane. 1H NMR 
(CDCl3): 7.79 (s, 1H), 7.61 (m, 3H), 7.51-7.30 (m, 14H), 7.23 (3H), 7.01 (m, 1H), 6.94 (m, 2H), 
5.14 (s, 2H), 5.09 (s, 2H), 4.64 (s, 2H), 4.16 (s, 2H), 2.18 (s, 3H). 13C NMR (CDCl3): 167.1, 
159.3, 157.5, 152.8, 138.7, 138.3, 137.8, 137.2, 137.0, 135.5, 133.6, 130.3, 130.1, 129.8, 129.7, 
128.8, 128.6, 128.5, 128.3, 128.0, 127.9, 127.6, 127.4, 126.4, 118.8, 115.0, 114.9, 113.2, 108.9, 
70.2, 70.1, 39.4, 33.3, 19.9. HRMS (m/z): MIA. 
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General protocol for the debenzylation of compounds 20bA-C, 20cB-C into compounds 
20dA-B, 20dD, 20eB and 20eD. The considered O-acetylated luciferin (1.05 mmol) and 10% 
palladium over charcoal (0.11 g, 0.105 mmol) were dispersed in ethyl acetate (20 mL), ethanol 
(20 mL) and acetic acid (6 mL). This was charged in hydrogen and stirred for 10-20 hours. Note: 
depending on the quality of the catalyst used, over-hydrogenation was sometime an issue, 
especially with the furan-bearing substrates. The resulting suspension was filtered, concentrated 
to dryness and the residue purified by chromatography as described below. Note: pre-adsorption 
of this residue over a small portion of silica gel before the chromatography was made using ethyl 
acetate without heating and no delay was taken before undertaking the purification by 
chromatography. 
 
 
2,8-Dibenzyl-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-yl acetate (20dA): This compound 
was obtained as a white cotton (0.1 g, 27% from 18aA) after a chromatography over silica gel 
(cyclohexane – ethyl acetate 4/1 to 3/1). 1H NMR (DMSO-d6): 9.64 (s, 1H), 8.54 (s, 1H), 7.89 
(m, 2H), 7.48 (m, 2H), 7.26 (m, 8H), 6.87 (m, 2H), 4.46 (s, 2H), 4.08 (s, 2H), 2.37 (s, 3H). 13C 
NMR (DMSO-d6): 168.5, 158.5, 151.9, 139.0, 138.4, 138.2, 135.3, 133.3, 129.7, 129.3, 129.1, 
128.8, 128.7, 127.9, 127.5, 126.8, 126.7, 115.9, 109.4, 39.2, 33.0, 20.7. HRMS (m/z): [M+H]+ 
calcd for C28H24N3O3: 450.1818, found, 450.1825. 
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8-Benzyl-2-(furan-2-ylmethyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-yl acetate (20dB): 
This compound was obtained as a white cotton (0.37 g, 39% from 18aB) after a chromatography 
over silica gel (cyclohexane – ethyl acetate 3/1). 1H NMR (DMSO-d6): 9.65 (s, 1H), 8.55 (s, 1H), 
7.90 (m, 2H), 7.55 (m, 1H), 7.47 (m, 2H), 7.27 (m, 2H), 7.22 (m, 1H), 6.88 (m, 2H), 6.39 (dd, 
1H, J = 1.8, 3.1 Hz), 6.19 (dd, 1H, J = 0.8, 3.1 Hz), 4.46 (s, 2H), 4.13 (s, 2H), 2.40 (s, 3H). 13C 
NMR (DMSO-d6): 168.4, 158.5, 152.0, 151.9, 142.4, 138.4, 138.3, 133.1, 132.6, 129.6, 129.2, 
128.8, 127.9, 127.5, 126.8, 115.9, 111.0, 109.4, 107.2, 39.1, 26.8, 20.8. HRMS (m/z): [M+H]+ 
calcd for C26H22N3O4, 440.1610, found, 440.1603. 
 
 
8-Benzyl-2-(4-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-yl acetate (20dD): 
This compound was obtained as a beige solid (0.10 g, 27% from 20bC) after a chromatography 
over silica gel (cyclohexane – ethyl acetate 2/1). 1H NMR (DMSO-d6) 9.65 (s, 1H), 9.20 (s, 1H), 
8.53 (s, 1H), 7.89 (m, 2H), 7.48 (m, 2H), 7.24 (m, 3H), 7.07 (m, 2H), 6.87 (m, 2H), 6.69 (m, 2H), 
4.46 (s, 2H), 3.96 (s, 2H), 2.37 (s, 3H). 13C NMR (DMSO-d6): 168.5, 158.4, 156.2, 151.8, 138.5, 
138.2, 136.0, 133.2, 130.2, 129.7, 129.1, 128.9, 128.7, 127.9, 127.6, 126.8, 115.9, 115.5, 109.3, 
39.2, 32.3, 20.7. HRMS (m/z): [M+H]+ calcd for C28H24N3O4: 466.1767, found, 466.1758. 
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8-Benzyl-2-(furan-2-ylmethyl)-6-(3-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-yl acetate (20eB): 
This compound was obtained as a red powder (0.12 g, 26% from 20cB) after a chromatography 
over silica gel (cyclohexane – ethyl acetate 2/1). 1H NMR (DMSO-d6) 9.53 (s, 1H), 8.67 (s, 1H), 
7.55 (m, 1H), 7.52 (m, 1H), 7.48 (m, 3H), 7.32-7.19 (m, 4H), 6.80 (ddd, 1H, J = 7.6, 2.0, 1.0 Hz), 
6.39 (dd, 1H, J = 3.2, 2.0 Hz), 6.19 (dd, 1H, J = 3.2, 1.0 Hz), 4.48 (s, 2H), 4.15 (s, 2H), 2.40 (s, 
3H). 13C NMR (DMSO-d6): 168.4, 158.2, 152.1, 151.9, 142.5, 138.3, 138.0, 133.4, 132.8, 130.0, 
129.6, 129.7, 129.4, 128.8, 126.9, 117.3, 116.0, 113.7, 111.1, 111.0, 107.2, 39.1, 20.8, 14.5. 
HRMS (m/z): [M+H]+ calcd for C26H22N3O4: 440. 1610, found, 440.1619. 
 
 
8-Benzyl-2-(3-hydroxybenzyl)-6-(4-hydroxyphenyl)imidazo[1,2-a]pyrazin-3-yl acetate (20eD): 
This compound was obtained as a yellow powder (0.11 g, 32%) after a chromatography over 
silica gel (cyclohexane – ethyl acetate 2/1). 1H NMR (DMSO-d6) 9.56 (s, 1H), 9.24 (s, 1H), 8.64 
(s, 1H), 7.50 (m, 4H), 7.25 (m, 4H), 7.08 (m, 2H), 6.83 (m, 1H), 6.70 (m, 2H), 4.48 (s, 2H), 3.97 
(s, 2H), 2.37 (s, 3H). 13C NMR (DMSO-d6): 168.6, 158.2, 156.2, 152.0, 138.4, 138.1, 137.9, 
136.2, 133.4, 130.2, 129.7, 129.1, 129.0, 128.8, 126.9, 117.4, 116.0, 115.6, 115.5, 113.7, 111.0, 
39.2, 32.3, 20.7. HRMS (m/z): [M+H]+ calcd for C28H24N3O4: 466. 1767, found, 466.1767. 
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General protocol for the generation of solutions of luciferins from the O-acetylated 
luciferin. 
 
The considered O-acetylated luciferin (1 mg) was dissolved in DMSO (0.2 mL) and then diluted 
by adding a solution of acidic ethanol (0.3 ml) made from the addition of 37 % hydrochloric acid 
(100 µl) on 100 % ethanol (12 mL). This 0.5 mL solution was incubated at 50°C for 2 to 3h to 
give a stock solution which was then stored at -80°C. As depicted in figure S1, the LC/MS 
monitoring of the hydrolysis of the O-acetylated luciferin 20a-B into the corresponding luciferin 
5a-B was complete and clean in less than two hours. 
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Figure S1. HPLC profiles, obtained on an Agilent apparatus, with a 3.5 µm XDB-C18 column, 
elution: 5:95 to 95:5 H2O/MeOH in 3.5 min, with constant 5 mM ammonium formate. Peak at tR 
= 5.5 is compound 5a-B (m/z [M+H]+ = 382), peak at tR = 6.2 min is the O-acetylated compound 
20a-B (m/z [M+H]+ = 424). 
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Biochemistry 
 
NanoKAZ expression, purification and quality validation 
The nanoKAZ luciferase5 was expressed from a codon-optimized sequence of the gene coding for 
the previously reported6 NanoLuc, the mutated catalytic domain of the luciferase from 
Oplophorus gracilostris featuring 16 amino acid substitutions. The gene nanoKAZ was 
synthetized by Eurofins (Germany) with carboxy-end His6-tag (in caps) and flanking region 
corresponding to the pET23 sequence (Novagen). 
 
Atggtcttcacactcgaagatttcgttggggactggcgacagacagccggctacaacctggaccaagtccttgaacagggaggtgtgtcca
gtttgtttcagaatctcggggtgtccgtaactccgatccaaaggattgtcctgagcggtgaaaatgggctgaagatcgacatccatgtcatcat
cccgtatgaaggtctgagcggcgaccaaatgggccagatcgaaaaaatttttaaggtggtgtaccctgtggatgatcatcactttaaggtgat
cctgcactatggcacactggtaatcgacggggttacgccgaacatgatcgactatttcggacggccgtatgaaggcatcgccgtgttcgacg
gcaaaaagatcactgtaacagggaccctgtggaacggcaacaaaattatcgacgagcgcctgatcaaccccgacggctccctgctgttccg
agtaaccatcaacggagtgaccggctggcggctgtgcgaacgcattctggcgCTCGAGCACCACCACCACCACCAC
TGA 
 
The pET23 plasmid was amplified with the forward and reverse oligonucleotides 
(Fwd:5’CTCGAGCACCACCACCACCACCAC3’; 
Rvr:5’GGTATATCTCCTTCTTAAAGTTAAAC3’, Eurofins) using a Q5 DNA polymerase, 
dNTP mix (New England BioLabs). PCR product was purified by electrophoresis on agarose gel 
(1%, Macherey-Nagel). Purified pET23 vector and the synthetic gene were assembly using 
NEBuilder HiFi assembly master mix (New England BioLabs). The assembled product (5 L) 
was used to transform NEB 5-alpha competent E. coli and grown overnight on 
LB/Agar/ampicillin in Petri dish. Isolated colonies were grown in liquid medium, plasmid was 
isolated and nucleotide sequence was performed to confirm the presence of the insert (Eurofins). 
The pET23-kaz was used to transform E.coli BL21 (DE3) to achieve high expression in E.coli. 
Cell were grown at 18 °C and IPTG was added to induce nanoKAZ production. After harvesting 
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the cells by centrifugation (1.5 L), pellet was resuspended in 50 mM Tris-HCl pH 8.0, 50 mM 
NaCl with protease inhibitors (Sigma) and lysozyme (0.1 mg/mL). Cells were disrupted by 
freezing-thawing cycle lysis method. DNase I (Sigma-Aldrich) was then added to remove DNA 
from the sample. 
The crude extract was centrifuged 30 min at 1250 g. The supernatant was collected and NaCl 
(500 mM), imidazole (20 mM) and Triton X100 (0.1%) were added. Then this cleared lysate was 
loaded on a His-Trap HP column (5 mL, GE-Healthcare) at a flow rate of 4 mL/min using an 
AKTA pure chromatography system (GE-Healthcare). The column was washed with 20 volumes 
of column with a running buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 20 mM imidazole) at 5 
mL/min. The nanoKAZ was eluted with a gradient of imidazole from 20 mM to 200 mM in 50 
mM Tris-HCl pH 8.0, 50 mM NaCl at 5 mL/min and fractions of 1 mL were collected in 96-
deepwell plate (GE-Heath). Catalytic activity of fractions was profiled using a luminometer 
Hydex by diluting 107 folds the fractions in PBS with 27 M of furimazine (8-benzyl-2-(furan-2-
ylmethyl)-6-phenylimidazo[1,2-a]pyrazin-3(7H)-one). The fractions of high activity were pooled, 
and loaded on a HiTrap Q column (1 mL, GE-Healthcare) equilibrated in 50 mM Tris-HCl pH 
8.0, NaCl 50 mM. The protein was eluted in 50 mM MES pH 6.5, 50 mM NaCl at 1 mL/min at 
18°C using the AKTA pure chromatography system. The fractions of 500 L were collected in 
96-deepwell plates and their activities were assayed as described above. The fractions of high 
activity were pooled. An UV-spectrum (240-300nm) was acquired for evaluating the 
concentration of nanoKAZ from the solution absorption at 280 nm. The extinction coefficient 
was estimated by the method of Gill and von Hippel7 from the residue sequence of nanoKAZ 
( 280nm = 24750 M
-1.cm-1). The specific activity is about 92·109 acquired photons / s / mg of 
nanoKAZ. 
 
As depicted in figure S2, the quality of the purified protein was assessed by loading a 2 L 
aliquot on a stain-free SDS gel (4–15% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Bio-
Rad). The gel was activated by UV trans-illumination for 5 min (Bio-Gel Doc XR Imaging 
System) and fluorescence of tryptophan in protein bands were imaged. The gel was then 
transferred on nitrocellulose (ECL membrane, GE-Healthcare) and revealed using a mouse HRP-
coupled IgG anti-His-tag (Invitrogen). 
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Figure S2. SDS-PAGE and western blot of purified nanoKAZ luciferase. The molecular 
weight scale (kDa) is indicated on the left. (A) The lanes from left to right show stained 
nanoKAZ bands (19 kDa) corresponding to 20, 10 and 5 g solution samples respectively. (B) 
The lane shows the immunoprint of nanoKAZ band (19 kDa, 10 g) revealed through its C-end 
His6-tag by a HRP-coupled anti-His tag in the presence of bioluminescent HRP substrate 
(Supersignal West Femto, ThermoFisher Scientific). 
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Bioluminescence assays 
 
In 96-well white flat bottom plate (Costar), 50 µL/well were loaded from a 1/50th dilution of the 
stock (5.4 mM) imidazo[1,2-a]pyrazin-3(7H)-ones solution in DPBS (Gibco) + 0.1% (v/v) 
Tween 20 (Sigma-Aldrich). Note: the pH of DPBS (Gibco) is between 7.0 and 7.3; results may 
vary with a different pH. Spontaneous luminescence emission intensity displayed by the different 
luciferin analogues was measured on 3 points using a Berthold CentroXS luminometer 
(integration time of 1 second, 22°C). The nanoKAZ solution (at 50 ng/L) was diluted 106 times in 
PBS/tween buffer and 50 L was added per well. The plate was orbitally shaked for 5 seconds, 
then the luminescence signal intensity was measured per well over 2 hours, integrating 1 s/well 
every 3 minutes at 22°C. Given the design of the experiment, the first measurement of 
luminescence occurred 20 seconds after addition of the luciferase. In order to get the maximum 
intensities for extremely fast-decaying substrates, we acquired individually kinetics for each of 
substrates for 4 minutes, starting 1 second after the injection of the enzyme in the well of the 
plate inside the plate reader.  
 
Note concerning the assumption that the number of detected photons per consumed 
substrate molecule is constant whatever the substrate concentration. 
 
As depicted in figure S3, the maximum measured light intensity is plotted versus initial substrate 
concentration we noticed that, for all the substrates studied, there is a signal intensity decrease at 
high concentration. We suggest the following three, not mutually exclusive, hypothesis to explain 
this observation. First, the substrate and reaction products absorb the light emission. Second, as 
for many enzymes, an excess of substrate inhibits the oxidation catalysis via an uncompetitive 
mechanism. Third, the photon emission occurring in the active site may be quenched by the 
excess of substrate present outside the active site.  
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Figure S3. Maximal light intensity vs substrate concentration. (A) The maximal light 
intensity (RLU/s) is plotted in plain lines versus substrate concentrations (10-6M) with the same 
enzyme concentration (1.24·10-12M). The kinetics fit with a Michaelis-Menten model (dashed 
lines). All substrates inhibit the detected light intensity, by extrapolation the initial reaction 
velocity v, at high concentration, suggesting an uncompetitive inhibition by excess of substrate. 
(B, C) The Lineweaver-Burk plots of 1/v (1/Light intensity in s/RLU) versus 1/S (M-1) are shown 
with two scales. The curvature along the 1/v axis is characteristic of uncompetitive inhibition by 
substrate excess. The extrapolation of the linear part is intercepted by the x-axis at the -1/K’M 
value, the inverse of the apparent Michaelis constant, and by the y-axis at the 1/V’max. (D,E) In 
the same plots shown with two scales of 1/v versus S, the extrapolation of the linear part is 
intercepted by the x-axis at the KI value, the dissociation constant of the second substrate 
molecule from the complex ES. 
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Light absorption of all the substrates 
 
Concerning the first hypothesis to explain this signal intensity decrease at high concentration, we 
measured the substrates absorption characteristics between 400 and 600 nm (table S1).  
 
Table S1, light absorption of all the substrates between 400 and 600 nm. 
Luciferins 3/5aB 4/5aA 5dA 5dB 1/5dD 5eB 5eD 
max (nm) 413 426 426 418 426 412 418 
max (M-1cm-1) 6294 7881 6973 7754 8950 6415 7692 
440 nm (M-1cm-1) 5010 7453 6594 6811 8326 5013 6496 
450 nm (M-1cm-1) 3946 6715 5779 5633 7137 4003 5244 
460 nm (M-1cm-1) 2964 5832 4781 4409 5734 3050 3981 
440-460 nm (M-1cm-1) 3974 6666 5718 5618 7066 4022 5240 
 
The light emissions observed with these substrates peak is between 440-460 nm. The absorptions 
of these compounds in solution peak between 413 and 426 nm with averaged molar extinction 
coefficients ( ) in between 440 and 460 nm of 3974 and 7066 M-1cm-1. At micromolar 
concentration, the absorption of light emitted by the substrate catalyzed oxidation is thus very 
weak in view of Beer-Lambert’s law (emitted light intensity = measured light intensity / e(  L c) 
where L is the half height of the solution in the plate well (mm-range) and c the substrate 
concentration in the 10-6-10-4 M range). Accordingly, substrate absorption should contribute but 
is too weak to account for the loss of light observed beyond 27 M of concentration for any 
tested substrate. 
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Kinetics analysis 
The apparent reaction rate (v’) is given by the measured light intensity (RLU/s) reflecting 
counted photons/s, depending on the real catalytic rate (kcat) and the yield of the measurement ( , 
the number of molecules catalyzed per RLU). The kinetics have been fitted using the Michaelis-
Mentel model drawn below considering 1) the luciferins (S) as the limiting substrates and O2 as 
saturating substrate in the experimental assay conditions (100 L) in a 6 mm-diameter well of 
multi-well plates, 2) the inhibition of the enzyme E by excess of substrate through the binding of 
a second substrate (ESS) on the Michaelis’ complex (ES) with the dissociation constant KI and 
the on (kSS,on) and off (kSS,off) binding constants, and 3) the stochastic inactivation of the enzyme 
(E*) along the reaction turn over decreasing exponentially the active enzyme population with the 
kinetic constant kinact. K’M is the apparent constant of Michaelis and V’max the apparent maximal 
reaction velocity. 
 
 
With  
 
 
 
 
 
43 
 
 
 
 
     
 
      
 
44 
 
      
 
 
 
Figure S4: Enzyme inactivation kinetics. The kinetics are plotted versus time with the same 
enzyme concentration and the same substrate concentration. These plots compare the fitting of 
the experimental data (red plain line) with the theoretical reaction velocity computed according to 
the described Michaelis-Menten model taking into consideration the irreversible inactivation of 
the enzyme (dashed black lines). 
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From these computations, the following kinetic parameters were obtained: 
 
 
3/5aB 4/5aA 5dA 5dB 1/5dD 5eB 5eD 
Imax (106 RLU/s) 1.69 3.28 2.05 3.11 0.23 1.98 0.10 
t½ (min) 74.29 19.34 3.22 0.33 20.96 32.27 148 
ΣI (106 RLU/s) 84.98 80.85 5.61 11.57 6.29 62.97 6.04 
K’M (10-6 M) 3.40 2.33 3.71 3.45 8.8 4.23 7.02 
k’cat (1018 RLU/s)  1.80 3.50 2.32 3.60 0.44 2.33 0.17 
molecules/RLU 1775 4581 12067 4463 101169 1804 70020 
KI (10
-6 M) 104.94 115.21 140.55 101.64 22.48 84.02 35.42 
KM (10
-6 M) 2.22 3.02 5.90 3.88 6.80 3.30 2.94 
kcat (mol/s·mol E)  106 534 932 535 1500 140 362 
kinact (10
-4 s-1) 1.5 5.2 425 375 3.8 4.5 3.1 
 
 
 
Plotting of the luciferase inactivation in the course of substrate catalyzed oxidation 
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As depicted in figure S5, the light emission intensity decreases with time: steep for “flash” (5dB) 
and slow (3/5aB) for “glow” substrates. For verifying if the reaction rate indicated by the photon 
emission (RLU/s) decreases with time, the same enzyme amount (62·10-18 mol) was added when 
indicated by the arrows for different concentrations of substrates indicated in the legend between 
brackets (10-6M). This demonstrates that enzyme is irreversibly inactivated during the kinetics as 
shown for luciferin 5dB an 3/aB. 
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Figure S5. Luciferase inactivation in the course of the catalyzed oxidation of 5dB and 3/5aB. 
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1H and 13C spectra 
 
 
51 
 
(3S,5R)-3-benzyl-5-phenylpiperazin-2-one (15a, first dia) 
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(3S,5R)-3-benzyl-5-phenylpiperazin-2-one (15a, first dia) 
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(3S,5S)-3-benzyl-5-phenylpiperazin-2-one (15a, second dia) 
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(3S,5S)-3-benzyl-5-phenylpiperazin-2-one (15a, second dia) 
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6-Benzyl-5-oxo-2-phenyl-2,3,4,5-tetrahydropyrazine 1-oxide (17a) 
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6-Benzyl-2-(4-(benzyloxy)phenyl)-5-oxo-2,3,4,5-tetrahydropyrazine 1-oxide (17b) 
 
85 
 
 
 
86 
 
 
87 
 
 
88 
 
 
 
89 
 
 
 
90 
 
 
 
91 
 
 
92 
 
 
 
93 
 
 
 
94 
 
 
95 
 
 
 
 
96 
 
 
97 
 
 
 
98 
 
 
 
99 
 
 
 
100 
 
 
 
101 
 
 
102 
 
 
 
103 
 
 
104 
 
 
 
105 
 
 
106 
 
 
 
 
107 
 
 
108 
 
 
 
109 
 
 
 
110 
 
 
 
111 
 
 
112 
 
 
 
113 
 
 
 
114 
 
 
 
 
115 
 
 
116 
 
 
 
 
117 
 
 
118 
 
 
 
 
119 
 
 
120 
 
 
 
121 
 
 
122 
 
 
 
123 
 
 
 
124 
 
 
 
125 
 
 
126 
 
 
 
127 
 
 
 
128 
 
 
 
129 
 
 
 
130 
 
 
 
